Exagen Inc. Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
Exagen (Nasdaq: XGN) reported second quarter 2026 revenue of $19.9 million, up 16% from $17.2 million in 2025, with record total revenue, test volume and a gross margin of 61.3%. AVISE CTD test volume grew 11% year over year and trailing twelve‑month average selling price rose 4% to $446 per test.
Net loss narrowed to $3.2 million from $4.4 million, while adjusted EBITDA improved to a loss of $0.1 million versus a $1.7 million loss a year earlier. Cash and cash equivalents were approximately $24.6 million at June 30, 2026. The company raised full‑year 2026 revenue guidance to $72–$75 million from $70–$73 million. Exagen also highlighted a published systematic review of over 3,100 patients across 14 medical centers supporting AVISE Lupus performance, showing AVISE CTD correctly identified about 25% of SLE patients missed by conventional markers.
Positive
- Revenue +16% YoY to $19.9 million in Q2 2026
- Gross margin 61.3%, up from 60.4% in Q2 2025
- Net loss reduced to $3.2 million from $4.4 million YoY
- Adjusted EBITDA improved to a $0.1 million loss from $1.7 million loss
- 2026 revenue guidance raised to $72–$75 million from $70–$73 million
- AVISE CTD volume +11% and trailing ASP up 4% to $446
- Clinical evidence review showed AVISE CTD detected ~25% of SLE cases missed by conventional markers
Negative
- Net loss $3.2 million and six‑month loss $7.2 million
- Operating expenses rose to $13.9 million from $13.0 million YoY
- Cash balance declined to $24.6 million from $32.2 million at December 31, 2025
- Interest expense of $1.2 million in Q2 2026
- Accumulated deficit reached $321.4 million as of June 30, 2026
- Common shares outstanding increased to 24.2 million from 22.9 million at year‑end 2025
News Explained
The completed quarter reports a higher common share count, reducing existing holders’ percentage ownership absent offsetting changes.
Exagen has completed and reported its second quarter ended
Market reaction after 2Q26 earnings report: XGN +34.40%
Following this news, XGN has gained 34.40%, reflecting a significant positive market reaction. Argus tracked a peak move of +14.5% during the session. Our momentum scanner has triggered 26 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $6.29. Trading volume is very high at 4.3x the average, suggesting strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Q1 earnings report | Positive | +34.9% | Record revenue, volume growth, improved EBITDA loss, and maintained full-year guidance |
| Jan 11 | Preliminary results | Positive | -6.2% | Projected revenue growth, higher ASP, increased cash, and preliminary unaudited results |
| Nov 04 | Q3 earnings report | Positive | -9.0% | Strong revenue growth, improved EBITDA loss, product launch, and reiterated guidance |
| Jul 29 | Q2 earnings report | Positive | +14.3% | Record revenue, higher test volume, expanded ASP, public offering, and guidance |
| May 05 | Q1 earnings report | Positive | +3.8% | Record revenue, higher ASP, testing-volume growth, credit facility, and guidance |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings announcements were positive in content, with three aligned reactions and two divergences over the selected historical period.
Key Terms
adjusted ebitda financial
non-gaap financial measure financial
clia-certified regulatory
cap-accredited regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Achieved record total revenue, test volume and trailing twelve-month ASP
Reduced net loss by nearly
Increased full-year revenue guidance to
CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Unaudited. In thousands, except ASP data. | ||||||||||||||||
| Revenue | $ | 19,941 | $ | 17,202 | $ | 37,247 | $ | 32,700 | ||||||||
| Gross margin | 61.3 | % | 60.4 | % | 60.2 | % | 59.7 | % | ||||||||
| Operating expenses | $ | 13,939 | $ | 13,025 | $ | 27,558 | $ | 25,513 | ||||||||
| Operating loss | $ | (1,722 | ) | $ | (2,630 | ) | $ | (5,136 | ) | $ | (5,995 | ) | ||||
| Net loss | $ | (3,196 | ) | $ | (4,439 | ) | $ | (7,163 | ) | $ | (8,191 | ) | ||||
| Adjusted EBITDA | $ | (114 | ) | $ | (1,721 | ) | $ | (2,274 | ) | $ | (4,229 | ) | ||||
| Trailing-twelve-month average selling price (ASP) | $ | 446 | $ | 428 | $ | 446 | $ | 428 | ||||||||
| Cash and cash equivalents | $ | 24,588 | $ | 30,033 | $ | 24,588 | $ | 30,033 | ||||||||
Second Quarter 2026 and Recent Corporate Highlights:
- Achieved record total revenue of
$19.9 million , an increase of16% compared to second quarter 2025. - Grew AVISE CTD test volume
11% compared to second quarter 2025. - Expanded AVISE CTD trailing twelve-month ASP to
$446 per test, an increase of$18 per test, or4% compared to second quarter 2025. - Drove a significant improvement in adjusted EBITDA, reporting a loss of
$0.1 million compared to a loss of$1.7 million in second quarter 2025. - Ended the quarter with approximately
$25 million in cash and cash equivalents. - Published a systematic review validating strong real-world AVISE Lupus performance in an analysis of over 3,100 patients across 14 medical centers, which demonstrated that use of AVISE CTD correctly identified approximately
25% of SLE patients missed by conventional markers.
“We continue to advance Exagen’s unique mission to bring clarity to autoimmune disease,” said John Aballi, President and Chief Executive Officer. “Second quarter financial results demonstrate the progress we’re making in improving the growth and operating profile of our business, putting us within reach of sustainable profitability and cash generation. At the same time, we are building on Exagen’s leadership in autoimmune diagnostics through continued investment in clinical evidence generation, pipeline innovation and AI-powered tools that support rheumatology workflows to strengthen our role in rheumatology decision-making.”
2026 Guidance
The Company increased full-year 2026 revenue guidance to
Conference Call and Webcast
- Date: August 4, 2026
- Time: 8:30 a.m. ET/ 5:30 a.m. PT
- U.S. dial-in: 877-407-0890
- International dial-in: +1 201-389-0918
- Webcast: Available via the Exagen Investor Relations website at investors.exagen.com
Replay: A telephone replay will be available until Tuesday, August 18, 2026:
- U.S. replay: 877-660-6853
- International replay: +1 201-612-7415
- Replay passcode: 13760979
- Webcast: A recording of the webcast will be available one hour after the call concludes via the Exagen Investor Relations website at investors.exagen.com
Use of Non-GAAP Financial Measures (Unaudited)
In addition to the financial results prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release contains the metric adjusted EBITDA, which is not calculated in accordance with GAAP and is a non-GAAP financial measure. Adjusted EBITDA is defined as net loss adjusted for interest income (expense), income tax expense (benefit), depreciation and amortization expense, stock‑based compensation expense, change in fair value of warrant liability, and certain other non‑cash, unusual or non‑recurring items, including, for example, losses on extinguishment of debt and changes in the fair value of warrant liabilities; we do not exclude normal, recurring, cash operating expenses from this measure. Such items could have a significant impact on the calculation of GAAP net loss.
Exagen uses adjusted EBITDA internally because the company believes these metrics provide useful supplemental information in assessing its operating performance reported in accordance with GAAP. Exagen believes adjusted EBITDA may enhance an evaluation of the operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses the company believes are not indicative of the ongoing performance. However, this non-GAAP financial measure may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes.
This non-GAAP financial measure is not meant to be considered in isolation or used as a substitute for net loss reported in accordance with GAAP, should be considered in conjunction with the financial information presented in accordance with GAAP, has no standardized meaning prescribed by GAAP, is unaudited, and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that Exagen may exclude for purposes of these non-GAAP financial measures, and the company may in the future cease to exclude items that it has historically excluded for purposes of these non-GAAP financial measures. Likewise, Exagen may determine to modify the nature of adjustments to arrive at these non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by the company in this press release and the accompanying reconciliation table have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on non-GAAP financial measures.
A reconciliation of net loss to non-GAAP adjusted EBITDA is provided in the financial schedules that are part of this press release.
About Exagen
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow Exagen on LinkedIn.
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies, positioning, and ambitions; evaluations and judgments regarding financial results and the potential implications of those results, potential future financial and business performance, including any improvements to adjusted EBITDA, ASP, net loss and potential profitability; the potential utility and effectiveness of Exagen’s services and testing solutions; the impact of Exagen’s revenue cycle management strategy on the timing of collections and cash burn; potential stockholder value and growth and full-year 2026 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; the potential effects of inflation and tariffs on Exagen’s margins; and changes in laws and regulations related to Exagen’s regulatory requirements. Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; and ability to obtain additional funding; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 10, 2026, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investors:
Tina Jacobsen, CFA
Exagen Inc.
ir@exagen.com
| Exagen Inc. Unaudited Condensed Statements of Operations (in thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | 19,941 | $ | 17,202 | $ | 37,247 | $ | 32,700 | ||||||||
| Cost of revenue | 7,724 | 6,807 | 14,825 | 13,182 | ||||||||||||
| Gross margin | 12,217 | 10,395 | 22,422 | 19,518 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative expenses | 12,513 | 11,542 | 24,579 | 22,746 | ||||||||||||
| Research and development expenses | 1,426 | 1,483 | 2,979 | 2,767 | ||||||||||||
| Total operating expenses | 13,939 | 13,025 | 27,558 | 25,513 | ||||||||||||
| Loss from operations | (1,722 | ) | (2,630 | ) | (5,136 | ) | (5,995 | ) | ||||||||
| Interest expense | (1,201 | ) | (1,124 | ) | (2,468 | ) | (1,669 | ) | ||||||||
| Loss on extinguishment of debt | — | (295 | ) | — | (295 | ) | ||||||||||
| Change in fair value of warrant liability | (426 | ) | (438 | ) | 456 | (438 | ) | |||||||||
| Other income (expense), net | 153 | 85 | 21 | 243 | ||||||||||||
| Loss before income taxes | (3,196 | ) | (4,402 | ) | (7,127 | ) | (8,154 | ) | ||||||||
| Income tax expense | — | (37 | ) | (36 | ) | (37 | ) | |||||||||
| Net loss | $ | (3,196 | ) | $ | (4,439 | ) | $ | (7,163 | ) | $ | (8,191 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.13 | ) | $ | (0.21 | ) | $ | (0.30 | ) | $ | (0.41 | ) | ||||
| Weighted-average number of shares used to compute net loss per share, basic and diluted | 24,164,569 | 21,085,749 | 24,012,761 | 19,830,265 | ||||||||||||
| Exagen Inc. Unaudited Condensed Balance Sheets (in thousands, except share and per share amounts) | ||||||||
| June 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 24,588 | $ | 32,220 | ||||
| Accounts receivable, net | 12,407 | 10,855 | ||||||
| Prepaid expenses and other current assets | 5,862 | 5,818 | ||||||
| Total current assets | 42,857 | 48,893 | ||||||
| Property and equipment, net | 6,565 | 6,938 | ||||||
| Operating lease right-of-use assets | 1,953 | 1,435 | ||||||
| Other assets | 560 | 756 | ||||||
| Total assets | $ | 51,935 | $ | 58,022 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,439 | $ | 4,153 | ||||
| Accrued and other current liabilities | 4,939 | 6,327 | ||||||
| Deferred revenue | 1,492 | 675 | ||||||
| Finance lease liabilities, current | 1,091 | 1,135 | ||||||
| Operating lease liabilities, current | 979 | 1,226 | ||||||
| Borrowings, current | 517 | 643 | ||||||
| Total current liabilities | 13,457 | 14,159 | ||||||
| Borrowings, non-current, net of discounts and debt issuance costs | 22,322 | 22,264 | ||||||
| Finance lease liabilities, non-current | 1,617 | 1,960 | ||||||
| Operating lease liabilities, non-current | 1,130 | 438 | ||||||
| Warrant liability | 1,193 | 1,752 | ||||||
| Total liabilities | 39,719 | 40,573 | ||||||
| Commitments and contingencies (Note 5) | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 24 | 23 | ||||||
| Additional paid-in capital | 333,637 | 331,708 | ||||||
| Accumulated deficit | (321,445 | ) | (314,282 | ) | ||||
| Total stockholders' equity | 12,216 | 17,449 | ||||||
| Total liabilities and stockholders' equity | $ | 51,935 | $ | 58,022 | ||||
| Exagen Inc. Reconciliation of Non-GAAP Financial Measures (UNAUDITED) | ||||||||||||||||
| The table below presents the reconciliation of adjusted EBITDA, which is a non-GAAP financial measure. See "Use of Non-GAAP Financial Measures (UNAUDITED)" above for further information regarding Exagen's use of non-GAAP financial measures. | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Adjusted EBITDA | ||||||||||||||||
| Net loss | $ | (3,196 | ) | $ | (4,439 | ) | $ | (7,163 | ) | $ | (8,191 | ) | ||||
| Other (income) expense | (153 | ) | (85 | ) | (21 | ) | (243 | ) | ||||||||
| Interest expense | 1,201 | 1,124 | 2,468 | 1,669 | ||||||||||||
| Loss on extinguishment of debt | — | 295 | — | 295 | ||||||||||||
| Change in fair value of warrant liability | 426 | 438 | (456 | ) | 438 | |||||||||||
| Income tax expense (benefit) | — | 37 | 36 | 37 | ||||||||||||
| Depreciation and amortization expense | 628 | 466 | 1,227 | 906 | ||||||||||||
| Stock-based compensation expense | 980 | 443 | 1,635 | 860 | ||||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | (114 | ) | $ | (1,721 | ) | $ | (2,274 | ) | $ | (4,229 | ) | ||||
